Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
10.82
+0.82 (8.20%)
At close: Oct 31, 2025, 4:00 PM EDT
10.77
-0.05 (-0.46%)
After-hours: Oct 31, 2025, 7:52 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $784.51M in the quarter ending September 30, 2025, with 11.68% growth. This brings the company's revenue in the last twelve months to $2.93B, up 9.50% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.93B
Revenue Growth
+9.50%
P/S Ratio
1.15
Revenue / Employee
$353,610
Employees
8,300
Market Cap
3.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
AMRX News
- 1 day ago - Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Amneal Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 days ago - Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol - GlobeNewsWire
- 4 days ago - Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches - GlobeNewsWire
- 4 weeks ago - Amneal to Report Third Quarter 2025 Results on October 30, 2025 - GlobeNewsWire
- 5 weeks ago - Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) - GlobeNewsWire
- 5 weeks ago - Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - GlobeNewsWire
- 7 weeks ago - Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewsWire